Despite findings from a new study of ACE-inhibitor use during the first trimester of pregnancy, the FDA will not change the drugs' warning labels right now, the agency said in a recent conference call. The study, "Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors," published recently in the New England Journal of Medicine, found a 2.7 times higher risk for birth defects when the mother was taking an ACE inhibitor during the first trimester of pregnancy.
FDA will wait to change ACEI labels
Despite findings from a new study of ACE-inhibitor use during the first trimester of pregnancy, the FDA will not change the drugs' warning labels right now, the agency said in a recent conference call. The study, "Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors," published recently in the New England Journal of Medicine, found a 2.7 times higher risk for birth defects when the mother was taking an ACE inhibitor during the first trimester of pregnancy. Currently, the drugs' labels contain a black box warning alerting women to stop using the class of drugs as soon as possible if they become pregnant as use during the second and third trimesters of pregnancy has been associated with injury and even death to the fetus. The FDA considers the study results to be "preliminary data" and will need to review additional data before making a labeling change, but the agency said it would notify the public about the new findings.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Challenges for Pharmacies in 2025: What to Expect and How to Prepare
January 8th 2025Pharmacy professionals are used to overcoming obstacles in this competitive, dynamic field. But the coming year will bring challenges affecting patient care, the industry workforce and their business. Pharmacies must be ready to do more than weather the storm; they need deliberate strategy and sophisticated tools to thrive amidst these obstacles. This white paper will discuss the issues and solutions that should be at the top of every pharmacy professional’s mind as they start the new year.